Drugs / GVB-2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06921317 | Nov 2025 → Dec 2027 expected | open-angle glaucoma | IVIEW Therapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | IVIEW Therapeutics Inc. | Results IVIEW Therapeutics’ Innovative Gene Therapy GVB-2001 Treats First Primary Open-Angle Glaucoma Patient iviewtherapeutics.com ↗
The patient has completed a two-week safety follow-up with no drug-related adverse events observed and a downward trend in intraocular pressure (IOP), representing an important advance in translating this first-in-class therapy into human use. |
| 2025-07-28 | IVIEW Therapeutics Inc. | Results IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO iviewtherapeutics.com ↗
Preclinical animal studies confirmed its long-lasting IOP-lowering effect—demonstrating a dose-dependent, stable reduction in IOP that was maintained across low-, medium-, and high-dose groups through Day 56. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | IVIEW Therapeutics Inc. | IVIEW Therapeutics’ Innovative Gene Therapy GVB-2001 Treats First Primary Open-Angle Glaucoma Patient iviewtherapeutics.com ↗ |
| 2025-07-28 | IVIEW Therapeutics Inc. | IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO iviewtherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVB-2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06921317 ↗ |
| Known as | ScAAV2-dnRhoA | “The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via intracameral injection to the anterior segment of the eye...” NCT06921317 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection” NCT06921317 ↗ |
| Route | Other | “injected intracamerally” NCT06921317 ↗ |